PEG2000-C-DMG
Based on 4 publication(s) in Google Scholar
PEG2000-C-DMG, a pegylated lipid, can be used for the preparation of Onpattro. Onpattro, a hepatically directed investigational RNAi therapeutic agent, harnesses this process to reduce the production of mutant and wild-type transthyretin by targeting the 3′ untranslated region of transthyretin mRNA.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.97%
- CAS No.: 1443687-74-8
- 화학식: C126H249NO52
- 분자량:2610.29
-
보관:
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) PEG2000-C-DMG
More
Biological Activity
Preparation of MC3 Lipid Nanoparticles
Here we provide lipid molar ratios for LNPs in FDA-approved Patisiran (a siRNA targets the transthyretin (TTR) mRNA). The molar ratio of lipids in this formulation is D-Lin-MC3-DMA : DSPC : Cholesterol : PEG2000-C-DMG = 50 : 10 : 38.5 : 1.5[1], and RNA to lipid weight ratio is 0.05 (wt/wt).
A. Lipid Mixture Preparation
1. Dissolve lipids in ethanol and prepare 10 mg/m stock solutions. The lipid stock solutions can be stored at 20°C for later use.
Note 1: The ionizable lipid is usually a liquid. Due to the viscosity, it should always be weighed rather than relying on the autopipette volume.
Note 2: Cholesterol in solution should be kept warm (>37°C) to maintain fluidity. Transfer the cholesterol solution promptly to avoid cooling.
2. Prepare the lipid mixture solution as described. For each mL of lipid mixture add the following: 548 μL of 10mg/mL D-Lin-MC3-DMA (HY-112251), 254 μL of 10mg/mL Cholesterol (HY-N0322), 134 μL of 10mg/mL DSPC (HY-W040193), and 64 μL of PEG2000-C-DMG (HY-145411) [2]. Mix the solutions thoroμghly to achieve a clear solution. This mixture contains 10 mg of total lipid.
Note 3: The choice of lipids and ratios may be changed as desired and this will affect the LNP properties (size, polydispersity, and efficacy) and the amount of mRNA required.
B. siRNA Preparation
1. Prepare a 166.7 μg/mL siRNA solution with 100 mM pH 5 sodium acetate buffer.
Note 4: The lipid:siRNA weight ratio influences the encapsulation efficiency. Other weight ratios may be prepared as alternative formulations and should be adjusted accordingly by user.
C. Mixing
There are three commonly used methods to achieve rapid mixing of the solutions: the pipette mixing method, the vortex mixing method, and the microfluidic mixing method. All these mixing methods can be used for various applications.
It is important to note that pipette mixing method and vortex mixing method may yield more heterogeneous LNPs with lower encapsulation efficiencies and is prone to variability. Microfluidic devices enable rapid mixing in a highly controllable, reproducible manner that achieves homogeneous LNPs and high encapsulation efficiency. Within these devices, the ethanolic lipid mixture and aqueous solution are rapidly combined in individual streams. LNPs are formed as the two streams mix and are then collected into a single collection tube.
1. Pipette Mixing Method:
1.1. Pipette 3 mL of the siRNA solution and quickly add it into 1 mL of the lipid mixture solution (A 1:3 ratio of ethanolic lipid mixture to aqueous buffer is generally used.) Pipette up and down rapidly for 20-30 seconds.
1.2. Incubate the resulting solution at room temperature for up to 15 minutes.
1.3. After mixing, the LNPs were dialyzed against PBS (pH 7.4) for 2 h, sterile filtered using 0.2 μm filters, and stored at 4°C.
2. Vortex Mixing Method:
1.1. Vortex 3 mL of siRNA solution at a moderate speed on the vortex mixer. Then, Quickly add 1 mL of the lipid mixture solution into the vortexing solution (A 1:3 ratio of ethanolic lipid mixture to aqueous buffer is generally used.). Continue vortexing the resulting dispersion for another 20-30 seconds.
1.2. Incubate the resulting solution at room temperature for up to 15 minutes.
1.3. After mixing, the LNPs were dialyzed against PBS (pH 7.4) for 2 h, sterile filtered using 0.2 μm filters, and stored at 4°C.
3. Microfluidic Mixing Method:
1.1 The 3 mL of siRNA buffer solution and 1 mL of the lipid mixture solution were mixed at a total flow rate of 12 mL/min (A 1:3 ratio of ethanolic lipid mixture to aqueous buffer is generally used.) in a microfluidic device.
Note 5: Parameters such as the flow rate ratio and total flow rate can be altered to fine-tune LNPs.
1.2. After mixing, the LNPs were dialyzed against PBS (pH 7.4) for 2 h, sterile filtered using 0.2 μm filters, and stored at 4°C.
Reference
1. Curr Issues Mol Biol. 2022 Oct 19;44(10):5013-5027.
2. Curr Protoc. 2023;3(9):e898.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1443687-74-8
-
Appearance Solid
-
분자량 2610.29
-
화학식 C126H249NO52
-
Color White to off-white
-
SMILES
CCCCCCCCCCCCCC(O[C@@H](COC(NCCCOCCOC)=O)COC(CCCCCCCCCCCCC)=O)=O.[45]
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Biomaterials
Lipid nanoparticles that co-deliver poly(I:C) and short peptide antigens elicit anti-tumor responses with vaccination. [Abstract]2026 Apr:327:123754. PMID: 41075431 -
J Control Release
Impact of ionizable lipid source on quality and stability of siRNA-loaded lipid nanoparticles. [Abstract]2026 Mar 14:114825. PMID: 41839265 -
-
Eur J Pharm Sci
Liposomes and lipid nanoparticles: a tutorial for advanced chemical and structural characterisation. [Abstract]2026 Jul 1:222:107556. PMID: 42142813
용액&용해도
DMSO : 100 mg/mL (38.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (0.96 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (0.96 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.3831 mL | 1.9155 mL | 3.8310 mL | 9.5775 mL |
| 5 mM | 0.0766 mL | 0.3831 mL | 0.7662 mL | 1.9155 mL | |
| 10 mM | 0.0383 mL | 0.1915 mL | 0.3831 mL | 0.9577 mL | |
| 15 mM | 0.0255 mL | 0.1277 mL | 0.2554 mL | 0.6385 mL | |
| 20 mM | 0.0192 mL | 0.0958 mL | 0.1915 mL | 0.4789 mL | |
| 25 mM | 0.0153 mL | 0.0766 mL | 0.1532 mL | 0.3831 mL | |
| 30 mM | 0.0128 mL | 0.0638 mL | 0.1277 mL | 0.3192 mL |
PEG2000-C-DMG Related Classifications
HY-145411 Related Classifications
Powered by Bioz